Tesamorelin

Growth Hormone Releasing Hormone Analog · 44 Amino Acids · Research Use Only

Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), modified with a trans-3-hexenoic acid group to enhance stability against enzymatic degradation. It is the basis for Egrifta, an FDA-approved treatment for HIV-associated lipodystrophy. In research settings it is studied for its ability to stimulate natural pituitary GH secretion, reduce visceral adiposity, improve body composition, and support cognitive function — without suppressing the body's natural GH feedback axis.

How it works: Tesamorelin binds selectively to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating pulsatile release of endogenous growth hormone. Unlike exogenous HGH, it works within the body's natural regulatory framework — IGF-1 negative feedback and somatostatin release remain intact, preventing supraphysiological GH spikes. Downstream effects include increased IGF-1 production, lipolysis in visceral adipose tissue, enhanced protein synthesis, improved insulin sensitivity, and neurotropic effects.

Research highlights:
- Falutz et al. (JCEM 2010): Tesamorelin reduced visceral fat by ~15% vs placebo over 26 weeks
- Stanley et al. (Lancet HIV 2019): Significantly reduced non-alcoholic fatty liver disease markers
- Cognitive studies: Elevated GH/IGF-1 via Tesamorelin linked to improved verbal memory and executive function in aging adults

Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight: 5135.8 g/mol
Form: Lyophilized powder
Purity: ≥98% (HPLC verified)
Storage: -20°C, away from light and moisture

⚠ RESEARCH USE ONLY. This product is intended for laboratory and in vitro research purposes only. Not for human or animal consumption. Must be 21+ to purchase. These statements have not been evaluated by the FDA.